Sennosides
| Evidence Level: L5 | Predicted Indications: 6 |
Table of Contents
- Sennosides
- Pharmacist Assessment Report
- Sennosides: From Constipation (Stimulant Laxative Use) to Hypotrichosis Simplex of the Scalp
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Sennosides: From Constipation (Stimulant Laxative Use) to Hypotrichosis Simplex of the Scalp
One-Sentence Summary
Sennosides are stimulant laxatives marketed in Canada in several single-ingredient and docusate-combination products. The TxGNN model predicts they may be effective for hypotrichosis simplex of the scalp, but no clinical trials and no publications currently support this prediction, and no biological link has been identified. The score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the licence records compiled for this report (sennosides are generally used as stimulant laxatives) |
| Predicted New Indication | Hypotrichosis simplex of the scalp |
| TxGNN Prediction Score | 0.9929 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 4 of 5; dormant: 1) |
| Number of DINs | 5 (marketed: 4) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the compiled data. From general pharmacology, sennosides are anthraquinone stimulant laxatives. Their active metabolite, rheinanthrone, acts on the colonic mucosa, increasing prostaglandin E2 release and altering water and electrolyte transport.
No known pathway connects this action to hair follicle biology or to the genetic causes of hypotrichosis simplex (for example CDSN, APCDD1 or RPL21 variants). The original indication (bowel regulation) and the predicted indication (a hereditary hair-loss disorder) are mechanistically unrelated.
The high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. The six top predictions for this drug (hypotrichosis simplex of the scalp, congenital hypotrichosis milia, diffuse alopecia areata, open-angle glaucoma, primary hereditary glaucoma and alopecia) all score between 0.9910 and 0.9929. Four of the six are hair-loss conditions. Such near-identical scores suggest a non-specific signal rather than a drug-specific finding.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02247390 | SANDOZ SENNA S | Not specified | Not specified |
| 00026123 | SENOKOT S | Not specified | Not specified |
| 02516209 | COLACE PLUS STIMULANT LAXATIVE | Not specified | Not specified |
| 02247134 | SENNA LAXATIVE AND DOCUSATE SODIUM TABLETS | Not specified | Not specified |
| 02246951 | SENNA S. TABLETS | Not specified | Not specified |
All five licences are currently valid.
Safety Considerations
Please refer to the package insert for safety information. No drug interaction records were found in the data compiled for this report, and no contraindications were identified from the knowledge graph.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no supporting clinical trials or literature (Evidence Level L5). There is no plausible mechanistic link between a colonic stimulant laxative and hair follicle disorders. The nearly identical scores across the top predictions point to a non-specific model signal rather than real repurposing potential.
To proceed, the following is needed:
- Mechanism of action data for sennosides, to allow a proper mechanistic-link analysis
- Health Canada package insert warnings and contraindications, which are required before any safety screening
- Approved indication text, dosage forms and manufacturer details for each Canadian licence
- Preclinical or mechanistic evidence showing that sennosides or their metabolites affect hair follicle biology
- A check of whether other predicted indications have stronger supporting evidence, since none of the six top predictions currently has any trials or literature
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.